Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110040 | 0.82 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL3496820 | 0.81 | DGAT1 (0.35) | DGAT1NPC1SMN1; SMN2 | |
| SCHEMBL20745837 | 0.81 | DGAT1 (0.33) | DGAT1NPC1 | |
| SCHEMBL1441485 | 0.80 | DGAT1 (0.36) | DGAT1NPC1SMN1; SMN2 | |
| SCHEMBL3389626 | 0.80 | DGAT1 (0.32) | DGAT1NPC1 | |
| SCHEMBL30789772 | 0.80 | DGAT1 (0.33) | DGAT1NPC1 | |
| SCHEMBL401354 | 0.80 | ALDH1A1 (0.39) | DGAT1NPC1 | |
| SCHEMBL31308722 | 0.80 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL5246866 | 0.79 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL31741697 | 0.79 | DGAT1 (0.32) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025130765-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-06-26 | — | — | WO | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | GENENTECH, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-113166142-B | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4347594-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | Genentech, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117425654-A | 2, 8-diazaspiro [4.5] decane compounds | 基因泰克公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-109651358-B | 4-aminopyridine derivative, pharmaceutical composition, preparation method and application thereof | 上海迪诺医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022253341-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | GENENTECH, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| CN-113166142-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112088157-A | Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors | 拉文纳制药公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3668882-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111171019-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2019034890-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | LATS1, LATS2, GLS2 | DGAT1 653/4885NPC1 2463/4885SMN1; SMN2 3384/4885 |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | DGAT1 4742/4885NPC1 2823/4885SMN1; SMN2 2979/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | DGAT1 4613/4885NPC1 4533/4885SMN1; SMN2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.